MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone301-251-5172
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.12 million
Profitability
Miscellaneous
Employees364
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings data on Wednesday, July, 31st. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.31. The biopharmaceutical company earned $10.59 million during the quarter, compared to analyst estimates of $17.58 million. MacroGenics had a negative return on equity of 54.52% and a negative net margin of 273.47%. View MacroGenics' Earnings History.
When is MacroGenics' next earnings date?
What price target have analysts set for MGNX?
11 analysts have issued twelve-month price objectives for MacroGenics' stock. Their predictions range from $19.00 to $50.00. On average, they expect MacroGenics' stock price to reach $32.7556 in the next twelve months. This suggests a possible upside of 145.7% from the stock's current price. View Analyst Price Targets for MacroGenics.
What is the consensus analysts' recommendation for MacroGenics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.
What are Wall Street analysts saying about MacroGenics stock?
Here are some recent quotes from research analysts about MacroGenics stock:
- 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (8/7/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019)
Has MacroGenics been receiving favorable news coverage?
Media headlines about MGNX stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. MacroGenics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for MacroGenics.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include Reata Pharmaceuticals (RETA), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), Myokardia (MYOK), Amicus Therapeutics (FOLD), Intercept Pharmaceuticals (ICPT), Biohaven Pharmaceutical (BHVN), Agios Pharmaceuticals (AGIO), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Xencor (XNCR), Cambrex (CBM) and Zai Lab (ZLAB).
What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 67)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)
Who are MacroGenics' major shareholders?
MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Invesco Ltd. (9.18%), BlackRock Inc. (9.00%), Vanguard Group Inc. (6.54%), Wasatch Advisors Inc. (2.91%), Rhenman & Partners Asset Management AB (1.76%) and Nuveen Asset Management LLC (1.63%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jeffrey Stuart Peters, Jon Marc Wigginton, Lynn Cilinski, Matthew K Fust and Thomas Spitznagel. View Institutional Ownership Trends for MacroGenics.
Which institutional investors are selling MacroGenics stock?
MGNX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Rhenman & Partners Asset Management AB, Bank of America Corp DE, Wells Fargo & Company MN, Pinnacle Associates Ltd. and Acadian Asset Management LLC. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View Insider Buying and Selling for MacroGenics.
Which institutional investors are buying MacroGenics stock?
MGNX stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Nuveen Asset Management LLC, Panagora Asset Management Inc., UBS Asset Management Americas Inc., Eversept Partners LP, Vanguard Group Inc. and Wasatch Advisors Inc.. View Insider Buying and Selling for MacroGenics.
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $13.33.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $651.74 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.
What is MacroGenics' official website?
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
